(Q35016160)

5 August 2017

title

Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? (English)

1 reference

Mycobacterium tuberculosis

5 August 2017

main subject

0 references

author name string

Robert C Goldman

series ordinal

1

1 reference

5 August 2017

publication date

18 September 2013

1 reference

5 August 2017

1 reference

5 August 2017

volume

93

1 reference

5 August 2017

issue

6

1 reference

5 August 2017

page(s)

569-588

1 reference

Totally drug-resistant tuberculosis in India.

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The evolution of extensively drug resistant tuberculosis (XDR-TB): history, status and issues for global control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

HTS promiscuity analyses for accelerating decision making

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High-throughput assays for promiscuous inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Enhancement of chemical rules for predicting compound reactivity towards protein thiol groups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Profiling the NIH Small Molecule Repository for compounds that generate H2O2 by redox cycling in reducing environments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Early identification of false positives in high-throughput screening for activators of p53-DNA interaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High-throughput screening and sensitized bacteria identify an M. tuberculosis dihydrofolate reductase inhibitor with whole cell activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Antituberculosis activity of the molecular libraries screening center network library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Leads for antitubercular compounds from kinase inhibitor library screens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Glycerol kinase of Escherichia coli is activated by interaction with the glycerol facilitator

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Molecular properties of WHO essential drugs and provisional biopharmaceutical classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

New tuberculosis drugs on the horizon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

High-resolution phenotypic profiling defines genes essential for mycobacterial growth and cholesterol catabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Bacterial proteins with cleaved or uncleaved signal peptides of the general secretory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Definition of novel cell envelope associated proteins in Triton X-114 extracts of Mycobacterium tuberculosis H37Rv

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Crystal structure of decaprenylphosphoryl-β-D-ribose 2'-epimerase fromMycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Discovery and validation of new antitubercular compounds as potential drug leads and probes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Screening a library of 1600 adamantyl ureas for anti-Mycobacterium tuberculosis activity in vitro and for better physical chemical properties for bioavailability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

MmpL genes are associated with mycolic acid metabolism in mycobacteria and corynebacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Design, synthesis and anti-tuberculosis activity of 1-adamantyl-3-heteroaryl ureas with improved in vitro pharmacokinetic properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The many faces of the adamantyl group in drug design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Use of the Adamantane Structure in Medicinal Chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxamide and N-benzyl-6',7'-dihydrospiro[piperidine-4,4'-thieno[3,2-c]pyran] analogues with bactericidal efficacy against Mycobacterium tuberculosis targeting MmpL3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Preliminary structure-activity relationships and biological evaluation of novel antitubercular indolecarboxamide derivatives against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Comprehensive identification of conditionally essential genes in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Genes required for mycobacterial growth defined by high density mutagenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Roles in inhibitor recognition and quinol oxidation of the amino acid side chains at positions of cyt b providing resistance to Qo-inhibitors of the bc1 complex from Rhodobacter capsulatus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The Pks13/FadD32 crosstalk for the biosynthesis of mycolic acids in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Cooperativity and biological complexity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The Interaction of Drugs with the Sarcoplasmic Reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Diffusion of dihydropyridine calcium channel antagonists in cardiac sarcolemmal lipid multibilayers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Interaction of 1,4 dihydropyridine calcium channel antagonists with biological membranes: lipid bilayer partitioning could occur before drug binding to receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The separate profile structures of the functional calcium pump protein and the phospholipid bilayer within isolated sarcoplasmic reticulum membranes determined by X-ray and neutron diffraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Favorable amphiphilicity of nimodipine facilitates its interactions with brain membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Molecular modeling approaches for the prediction of the nonspecific binding of drugs to hepatic microsomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Effects of lipid chain length on molecular interactions between paclitaxel and phospholipid within model biomembranes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Lipid-binding surfaces of membrane proteins: evidence from evolutionary and structural analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

How lipids and proteins interact in a membrane: a molecular approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

beta-Barrel membrane bacterial proteins: structure, function, assembly and interaction with lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Stoichiometry of lipid interactions with transmembrane proteins--Deduced from the 3D structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Amphipathic antenna of an inward rectifier K+ channel responds to changes in the inner membrane leaflet

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The potassium channel KcsA: a model protein in studying membrane protein oligomerization and stability of oligomeric assembly?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Structural Determinants of Specific Lipid Binding to Potassium Channels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Lipid-protein interactions of integral membrane proteins: a comparative simulation study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Molecular simulations and lipid-protein interactions: potassium channels and other membrane proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The potassium channel KcsA and its interaction with the lipid bilayer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Lipid interactions with bacterial channels: fluorescence studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Heterogeneity in the Binding of Lipid Molecules to the Surface of a Membrane Protein: Hot Spots for Anionic Lipids on the Mechanosensitive Channel of Large Conductance MscL and Effects on Conformation†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Penetration of lipid chains into transmembrane surfaces of membrane proteins: studies with MscL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The interaction of the antimicrobial peptide gramicidin S with lipid bilayer model and biological membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The macrolide-bacterium interaction and its biological basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Anti-Candida activity of cispentacin: the active transport by amino acid permeases and possible mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mechanism of isoniazid uptake in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Intracellular accumulation of norfloxacin in Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Uptake and binding of 14C-ethambutol by tubercle bacilli and the relation of binding to growth inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The arabinosyltransferase EmbC is inhibited by ethambutol in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mycobacterium tuberculosis embB codon 306 mutations confer moderately increased resistance to ethambutol in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Effects of pyrazinamide on fatty acid synthesis by whole mycobacterial cells and purified fatty acid synthase I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Inhibition of isolated Mycobacterium tuberculosis fatty acid synthase I by pyrazinamide analogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Pyrazinoic acid and its n-propyl ester inhibit fatty acid synthase type I in replicating tubercle bacilli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Para-aminosalicylic acid acts as an alternative substrate of folate metabolism in Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Targeting the mycobacterial envelope for tuberculosis drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mycobacterial outer membranes: in search of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The Envelope of Mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mycobacterial porins--new channel proteins in unique outer membranes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Nutrient acquisition by mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

The functions of OmpATb, a pore-forming protein of Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Outer membrane pore protein prediction in mycobacteria using genomic comparison

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Molecular basis of clarithromycin activity against Mycobacterium avium and Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mycobacterium tuberculosis CYP130: CRYSTAL STRUCTURE, BIOPHYSICAL CHARACTERIZATION, AND INTERACTIONS WITH ANTIFUNGAL AZOLE DRUGS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Interaction of Mycobacterium tuberculosis CYP130 with Heterocyclic Arylamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Design and synthesis of 1H-1,2,3-triazoles derived from econazole as antitubercular agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Synthesis and antitubercular activity of monocyclic nitroimidazoles: insights from econazole

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Click chemistry approach for bis-chromenyl triazole hybrids and their antitubercular activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Resistant mutants of Mycobacterium tuberculosis selected in vitro do not reflect the in vivo mechanism of isoniazid resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A collaborative database and computational models for tuberculosis drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Drug discovery beyond the 'rule-of-five'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Chemoinformatic analysis of combinatorial libraries, drugs, natural products, and molecular libraries small molecule repository

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A structure-permeability study of small drug-like molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A practical view of 'druggability'.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Selection criteria for drug-like compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Molecular properties that influence the oral bioavailability of drug candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A comparison of physiochemical property profiles of development and marketed oral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Going further than Lipinski's rule in drug design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Ligand Efficiency Indices (LEIs): More than a Simple Efficiency Yardstick

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

AtlasCBS: a web server to map and explore chemico-biological space.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

A sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Strong Inference: Certain systematic methods of scientific thinking may produce much more rapid progress than others

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Ask the experts: past, present and future of the rule of five

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Chris Lipinski discusses life and chemistry after the Rule of Five

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Let's get specific: the relationship between specificity and affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Synthesis of hydrophobic N'-mono and N',N"-double alkylated eremomycins inhibiting the transglycosylation stage of bacterial cell wall biosynthesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Synthesis and mode of action of hydrophobic derivatives of the glycopeptide antibiotic eremomycin and des-(N-methyl-D-leucyl)eremomycin against glycopeptide-sensitive and -resistant bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Genetic basis for activity differences between vancomycin and glycolipid derivatives of vancomycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Ligand binding in the conserved interhelical loop of CorA, a magnesium transporter from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Construction of a series of vectors for high throughput cloning and expression screening of membrane proteins from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

1H, 15N and 13C backbone resonance assignment of Rv1567c, an integral membrane protein from Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Uniformly aligned full-length membrane proteins in liquid crystalline bilayers for structural characterization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Expression of membrane proteins from Mycobacterium tuberculosis in Escherichia coli as fusions with maltose binding protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Structural biology of transmembrane domains: efficient production and characterization of transmembrane peptides by NMR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Identification of Mycobacterium tuberculosis H37Rv integral membrane proteins by one-dimensional gel electrophoresis and liquid chromatography electrospray ionization tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Cloning and expression of multiple integral membrane proteins from Mycobacterium tuberculosis in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Daptomycin: a review of properties, clinical use, drug delivery and resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Telavancin: a novel lipoglycopeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Cellular pharmacokinetics of telavancin, a novel lipoglycopeptide antibiotic, and analysis of lysosomal changes in cultured eukaryotic cells (J774 mouse macrophages and rat embryonic fibroblasts).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

Accumulation of norfloxacin by Mycobacterium aurum and Mycobacterium smegmatis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Porins in the cell wall of Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Mefloquine is active in vitro and in vivo against Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.TUBE.2013.09.003

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TUBE.2013.09.003

1 reference

5 August 2017

1 reference